RxDoctor Payments Data

William Raffo, MD

Nephrology · Santa Cruz, CANPI 1659356137

Payments from drug & device makers

$12,248in general payments, 2019–2025

Across 31 payments — averaging $395.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$7K
  • Calliditas Therapeutics US Inc.$3K
  • Baxter Healthcare$2K
  • Bayer$186
  • AstraZeneca$178
  • Travere Therapeutics, Inc.$125
  • plus $129 from 4 others

What the payments were for

  • Consulting fees$4,35036%
  • Speaking & faculty fees$4,25035%
  • Travel & lodging$2,19618%
  • Food & beverage$1,44012%
  • Education$120%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,248 in reported general payments places this provider in the 75th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$266,371
Medicare patients
369
Services billed
2,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol74$84,423
JardianceEmpagliflozin59$64,386
XphozahTenapanor Hcl11$39,262
KerendiaFinerenone28$25,778
VeltassaPatiromer Calcium Sorbitex15$24,614
LokelmaSodium Zirconium Cyclosilicate23$20,175
Sevelamer Carbonate28$9,943
Olmesartan Medoxomil89$1,603
Nifedipine ErNifedipine22$1,539
Valsartan39$1,430
Doxazosin Mesylate26$925
Torsemide22$851
Midodrine Hcl19$832
Spironolactone13$702
Amlodipine Besylate93$651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$178$104,59897 claims
BayerKerendia$186$25,77828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,341 nephrology providers in California.

Other nephrology in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →